!!! The World Mycotoxin Forum – 14th conference – 9-11 October 2023 !!!
WMFmeetsBelgium will offer an excellent way to network, share ideas, and formulate recommendations and conclusions on how to close knowledge gaps, including:
- Presentations and discussions in plenary meetings and parallel sessions
- Poster sessions
- Young scientist sessions
- company pitches, case studies, and industry updates covering a wide range of topics
- Workshops and demonstrations
- A concurrent instrument/manufacturers exhibition providing information on equipment, products, and services.
This research unit includes following themes: 1. the impact of the agro-ecosystem and related agricultural practices on the occurrenco of toxigenic moulds, 2. physiological consequences of toxin-production of the mould, 3. diversity of toxigenic moulds in several crops and matrices and 4. follow-up of new emerging toxigenic moulds in agricultural and horticultural crops.
This research unit entails mycotoxin occurrence studies in cereal-based food and feed using different analytical techniques. These techniques include screening (ELISA-based rapid tests, quantum dots, biosensors, …), confirmative (UPC² and LC-MS/MS) and innovative methodologies (molecularly imprinted polymers, MIPs). MYTOX is also specialized in metabolomics and untargeted screening using state-of-the-art high resolution mass spectrometry.
Mycotoxins and Human Health
This research unit includes all research projects in relation to the occurrence of mycotoxins and its effects on human health; epidemiological studies; risk assessment studies and scenario analyses. Mycotoxins are manifested in humans by acting on the immune system, the gastro-intestinal tract and by the development of plausible carcinogenic effects. Collaborations with WHO and IARC have been set, which enables MYTOX to expand this research unit.
Mycotoxins and Animal Health
This research unit studies the occurrence of mycotoxins and its influence on animal health. Research entails 1. toxicity, 2. toxicokinetics (absorption, distribution, metabolism and excretion (ADME), including animal models for humans), 3. residues in tissues in relation to public health, 4. interaction with the pathogenesis of infection diseases, 5. interaction with disposition and kinetics of pharmaceutics and 6. evaluation of the safety and efficacy of mycotoxin binders and detoxifiers.